Stopped: Paused due to change in staffing arrangements
The goal of this case series is to explore whether a talking therapy, specifically Cognitive Behavioural Therapy (CBT) is acceptable and feasible in the management of mood-driven impulsive behaviours in people with bipolar disorder (BD). The main questions it aims to answer are: * Whether CBT Is a feasible intervention for participants with BD who report mood-driven, problematic impulsive behaviours. * Whether CBT for mood-driven, problematic impulsive behaviours (CBT-PIB) is acceptable to service users with BD and therapists. * Whether clinical outcomes are consistent with the potential for this novel intervention to offer clinical benefit to participants with BD. The study also hopes to: * conduct a preliminary examination of the safety of CBT-PIB and the research procedures. * gather information on the potential mechanisms of action of CBT-PIB and, * gather information on the types of mood-driven impulsive behaviours individuals with BD may seek support for. Participants will: * be offered up to 12 individual sessions of CBT focusing on mood-driven impulsive behaviours. * be asked to complete a battery of self-report measures (5) when they enter the study and at the start and end of treatment. * be asked to track mood and impulsive behaviours by completing a brief set of measures (3) weekly during the two-week baseline phase, the intervention phase and the 2-week post-intervention phase. * be asked to complete a survey on the acceptability of the intervention and * be invited to an optional semi-structured interview on their research experience.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Overall acceptability and feasibility of the CBT protocol measured by the Client Satisfaction Questionnaire CBT-PIB
Timeframe: Post-intervention at week 16
rates of clinically significant and reliable change in mood measured by the Patient health questionnaire (PHQ-9)
Timeframe: Through study completion, an average of 18 weeks
rates of clinically significant and reliable change in symptoms of mania measured by the Altman Self-Rating Mania Scale
Timeframe: Through study completion, an average of 18 weeks
Changes in management of impulsivity measured by the Visual Analogue Scale
Timeframe: Through study completion, an average of 18 weeks
Number of participants with intervention-related adverse events assessed by the adverse events form
Timeframe: Through study completion, an average of 18 weeks